Interventions and Clinical Trials

In the News

Muhas don is new IHI board member

Prof. Kaaya. Ifakara Health Institute (IHI) Board of Governors (BOG) has appointed Prof. Sylvia Kaaya member of the IHI Board of Trustees (BOT) effective Wednesday January 10, 2018. The appointment …

Marcel steps down from IHI boards

Prof. Marcel Tanner has stepped down as Ifakara Health Institute (IHI) member of the Board of Trustees (BOT) and Board of Governors (BOG) effective Wednesday January 10, 2018. The Former …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …


The department conducts trials on drugs, diagnostics and vaccines for Tuberculosis (TB), HIV, Malaria and other diseases including respiratory pathogens,  zoonotic diseases, arboviruses, and various emerging and re-emerging infections. The department is supported by two laboratories with state of the art facilities at Ifakara and Bagamoyo Branches. The department is also expanding its portfolio to include non-communicable diseases, which are on the rise even in developing countries. Though we were previously working mostly on malaria, we have in recent years began work on development and testing of new TB drugs, given that what we have today have been in use for over 50 years. At our Chronic Diseases Clinic in Ifakara, we offer high quality HIV clinical care, while at the same time training researchers to improve the clinical care of HIV-infected people.  Moreover, IHI laboatories are continuously improving the diagnostic capacity, to serve IHI research projects and collaborators both within and outside the country. Our immunology department has grown in human capacity and equipment to analyze samples for different TB and malaria clinical trials.

In recent years scientists in the department have pioneered multiple innovative ways to assess vaccine candidates on malaria challenge study with infectious sporozoites. We are currently also providing technical support in other countries to start and implementing clinical trials. For example, we have a group now based in Equitorial Guinea supporting large-scale vaccine trial programs there. The department strives to strengthen the capacity to conduct clinical trials on infectious diseases including training IHI staff at Masters and PhD level. IHI is now firmly established as a dependable site where trials could be conducted in the future. The department staff are multidisplinary, consisting of statisticians, physicians, epidemiologists, public health specialists and social scientists.

Key Contacts

Head of Department

Deputy Heads of Department

Administrative Support


Evaluation of Cepheid GeneXpert Omni combined with the Xpert MTB/RIF Ultra in Primary Health Care in Tanzania

Evaluation of whole sporozoite vaccines for malaria elimination

Safety and immunogenicity of direct venus inoculation of Plasmodium falciparum sporozoite vaccine in adults, children and infants

Safety, immunogenicity and efficacy of intravenously administered attenuated Plasmodium falciparum sporozoite vaccine

Providers’ compliance to malaria treatment using Artemisinin-based combination therapy-ACTs in Tanzania

Evaluation of intravenous iron supplementation compared to oral supplementation among women with iron-deficient anemia

Zoonotic viral sharing among bats, primates and people in high-risk areas in Tanzania

Evaluation of Lopinavir-based anti-retroviral therapy for HIV-Infected children: a phase IIIb clinical trial in Ifakara

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

Screening and treatment of cryptococcal meningitis in Kilombero and Ulanga districts in Tanzania

Kilombero and Ulanga antiretroviral cohort study (KIULARCO)

Tanzania lung health study: prevalence and risk of chronic obstructive pulmonary disease

Malaria in Pregnancy Preventive Alternative Drugs(MiPPAD)

Epidemiology and molecular monitoring of HIV drug resistance in Tanzania

© Ifakara Health Institute (IHI), 2016